Panagora Asset Management Inc Otonomy, Inc. Transaction History

Panagora Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$3.16 - $4.36 $82 - $113	-26 Closed	0 $0
Q2 2020 Aug 12, 2020	SELL	$1.87 - $3.84 $3,519 - $7,226	-1,882 Reduced 98.64%	26 $0
Q3 2019 Nov 12, 2019	SELL	$2.12 - $2.86 $30,445 - $41,072	-14,361 Reduced 88.27%	1,908 $5,000
Q2 2019 Aug 09, 2019	SELL	$2.35 - $3.09 $232 - $305	-99 Reduced 0.6%	16,269 $45,000
Q1 2019 May 15, 2019	BUY	$1.8 - $2.97 $19,692 - $32,491	10,940 Added 201.55%	16,368 $43,000
Q4 2018 Feb 14, 2019	SELL	$1.51 - $2.93 $158 - $307	-105 Reduced 1.9%	5,428 $10,000
Q3 2018 Nov 13, 2018	SELL	$2.6 - $3.95 $75,649 - $114,929	-29,096 Reduced 84.02%	5,533 $15,000
Q2 2018 Aug 14, 2018	BUY	$3.7 - $4.75 $58,289 - $74,831	15,754 Added 83.46%	34,629 $133,000
Q1 2018 May 15, 2018	SELL	$4.05 - $6.1 $159,825 - $240,724	-39,463 Reduced 67.65%	18,875 $79,000
Q4 2017 Feb 14, 2018	BUY	$2.8 - $5.55 $163,346 - $323,775	58,338	58,338 $324,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Panagora Asset Management Inc with notifications on news.